NATURE OF THE ORGANIZATION AND BUSINESS (Details Narrative) - USD ($)														1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Jul. 07, 2024	Jun. 07, 2024	Jan. 16, 2024	Dec. 11, 2023	Oct. 17, 2023	Sep. 26, 2023	Jul. 17, 2023	Apr. 17, 2023	Mar. 31, 2023	Mar. 21, 2023	Feb. 06, 2023	Feb. 04, 2023	Jan. 18, 2022	Feb. 28, 2022	Jun. 30, 2024	Mar. 31, 2024	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Aug. 07, 2024	Dec. 12, 2023	Jun. 30, 2023	Sep. 30, 2022	Dec. 31, 2021	Feb. 22, 2021	Jan. 22, 2021	Apr. 25, 2019	Jun. 30, 2018	Apr. 01, 2016
Common stock per share																	$ 0.01		$ 0.01						$ 0.01
Payments to acquire businesses, net of cash acquired													$ 460,000
Milestone payments													3,460,000
Conversion of stock converted													507,000
Asset acquisition closing														$ 63,000
Retained Earnings (Accumulated Deficit)																	$ 235,370,384		$ 214,265,236
Proceeds																		$ 899,567
Cash																				$ 32,600,000
Cash on hand																	37,587,253		33,146,725
Shares and Securities [Member]
Raise up funds	$ 150,000,000.0	$ 150,000,000.0
Medifast Inc [Member]
Payments to acquire businesses, gross															$ 3,000,000	$ 2,000,000			$ 5,000,000
Collaboration amount				$ 10,000,000																	$ 5,000,000
Consideration to be transferred															$ 2,500,000	$ 2,500,000
Avenue Facility [Member]
Credit facility										$ 40,000,000							2,000,000
Proceeds from line of credit						$ 5,000,000				15,000,000
Uncommitted term loans										$ 20,000,000
Line of credit, expiration date										Oct. 01, 2026
Warrants to purchase										$ 1,200,000
Warrants exercise price										$ 1.24
Debt conversion amount										$ 2,000,000
Conversion price										$ 1.49
Line of credit, description										The Company is subject to certain affirmative and negative covenants under the Avenue Facility, including the requirement, beginning on the closing date, to maintain at least $5 million of unrestricted cash to be tested at the end of each month, and beginning on the period ended September 30, 2023, and at the end of each quarter thereafter, a trailing six-month cash flow, subject to certain adjustments as provided by the Avenue Credit Agreement, of at least $2 million.
Credit facility outstanding																	$ 19,000,000
Credit facility interest rate description																	(i) the sum of 4.75% plus the Prime Rate (as defined in the Avenue Supplement) and (ii) 12.50%. Payments are interest only for up to 24 months and then fully amortized thereafter.
First of Five Quarterly Installment [Member]
Stock issued during period shares new issues											337,895
Second of Five Quarterly Installment [Member]
Stock issued during period shares new issues								455,319
Third of Five Quarterly Installment [Member]
Stock issued during period shares new issues							158,129
Fourth of Five Quarterly Installment [Member]
Stock issued during period shares new issues					117,583
Fifth Quarterly Installment [Member]
Stock issued during period shares new issues			95,821
Minimum [Member] | Avenue Facility [Member]
Credit facility interest rate																	1.00%
Maximum [Member] | Avenue Facility [Member]
Credit facility interest rate																	3.00%
First and Second Anniversaries [Member]
Milestone payments													$ 1,730,000
Stock Purchase Agreement [Member]
Payments to acquire businesses, net of cash acquired												$ 250,000
Payments to acquire businesses, gross												460,000
Stock Purchase Agreement [Member] | Minimum [Member]
Payments to acquire businesses, net of cash acquired												$ 3,670,000
Asset Purchase Agreement [Member]
Consideration paid														4,000,000.0			$ 500,000
Business acquisition periodic payments														$ 500,000
Percentage of payment acquisition														15.00%
Medifast Private Placement [Member]
Shares issued				1,224,425
Shares issued per share				$ 8.1671
Proceeds				$ 10,000,000
ATM Sales Agreement [Member]
Proceeds from issuance of common stock	$ 53,300,000
Proceeds from sale of securities		$ 53,300,000															53,300,000
2024 Shelf [Member]
Proceeds from sale of securities																	$ 150,000,000.0
LegalSimpli Software, LLC [Member]
Voting interests acquired																												51.00%
Immudyne PR LLC [Member]
Ownership interest																													78.20%
Conversion Labs PR [Member]
Ownership interest																											100.00%
WorkSimpli Software LLC [Member]
Ownership interest									74.10%										73.30%			73.30%	73.60%	85.60%		85.60%		51.00%
Number of membership interest units redeemed									500
Conversion Labs PR LLC [Member] | Option Agreement [Member]
Ownership interest																						73.30%
Conversion Labs PR LLC [Member] | Option Agreement [Member] | Minimum [Member]
Ownership interest																						74.10%	85.60%
Conversion Labs PR LLC [Member] | Option Agreement [Member] | Maximum [Member]
Ownership interest																						73.30%	73.60%